Company Description

Resilion Therapeutics is a start-up biotechnology company focused on treatment resistance — one of oncology’s most urgent challenges. Resilion is developing first-in-class sweeping antibodies designed to neutralize resistance pathways and transform resistant “cold tumors” into immune-responsive “hot tumors.” Its lead asset, RES-101, targets Osteopontin (OPN) — a key driver of chemoresistance across ovarian, colorectal, liver, and cervical cancers. By blocking the OPN–CD44 interaction, RES-101 disrupts oncogenic signaling and restores sensitivity to existing therapies.